Latest Breaking News On - Teatorrhoeic hepatosis - Page 19 : comparemela.com

Lanifibranor, a first-in-class pan-PPAR agonist, hits the primary and key secondary end points in a phase 2b trial of patients with noncirrhotic, highly active nonalcoholic steatohepatitis.

New havenUnited statesYale universityJamile wakim flemingGuadalupe garcia tsaoInventiva pharmaSvenm francqueDivision of gastroenterologyAntwerp university hospitalYale university school of medicineMedscape medicalNew england journalDigestive diseases sectionYale university schoolCleveland clinicNonalcoholic steatohepatitis